BioPharmSignal logoBioPharmSignal

Biotech News

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

Certara (CERT)CertaraEarnings

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb.

Related news

CERTCertara2026-01-29 13:30 EST

Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2026

CERTCertara2026-08-04 11:00 EST

Certara Reports Second Quarter 2026 Financial Results

View all latest news

Certara

Model-Informed Drug Development Certara provides biosimulation software and technology-enabled services used throughout drug discovery, clinical development and regulatory review. Its tools help predict how medicines behave in different patients and dosing scenarios. Software Portfolio The company's software includes pharmacokinetic,...

Recent company news

CERTCertara2026-08-04 11:00 EST

Certara Reports Second Quarter 2026 Financial Results

CERTCertara2026-07-15 20:15 EST

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

CERTCertara2026-07-07 12:00 EST

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

CERTCertara2026-06-17 20:30 EST

Certara Announces CFO Transition

CERTCertara2026-05-18 20:15 EST

Certara to Participate in Upcoming Investor Conferences

Stock data

Close
8.13 USD
Market cap
874.27M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States